Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumors. Eligible patients were adults with progressive, advanced, well-differentiated pancreatic NETs. One on-treatment death in the placebo group was attributed to disease progression.
